IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Meridian Wealth Advisors LLC

Meridian Wealth Advisors LLC decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 14.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,771 shares of the medical research company's stock after selling 2,407 shares during the quarter. Meridian Wealth Advisors LLC's holdings in IQVIA were worth $2,903,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. GSA Capital Partners LLP purchased a new position in shares of IQVIA in the 3rd quarter valued at approximately $230,000. Empowered Funds LLC lifted its stake in shares of IQVIA by 33.9% during the third quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company's stock worth $814,000 after buying an additional 871 shares during the period. Pathstone Holdings LLC grew its holdings in shares of IQVIA by 4.8% during the third quarter. Pathstone Holdings LLC now owns 14,492 shares of the medical research company's stock valued at $3,434,000 after buying an additional 667 shares during the last quarter. Caprock Group LLC increased its position in shares of IQVIA by 11.7% in the 3rd quarter. Caprock Group LLC now owns 3,003 shares of the medical research company's stock valued at $712,000 after acquiring an additional 315 shares during the period. Finally, Prospera Financial Services Inc purchased a new position in IQVIA in the 3rd quarter worth $245,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQV traded down $5.04 during midday trading on Tuesday, hitting $181.07. 1,565,977 shares of the company traded hands, compared to its average volume of 1,239,209. The company has a market capitalization of $31.93 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 1.99 and a beta of 1.50. The business has a 50 day simple moving average of $194.58 and a two-hundred day simple moving average of $207.73. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $254.54.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. UBS Group dropped their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Truist Financial reiterated a "buy" rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Barclays reduced their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Stifel Nicolaus cut their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.